← SynDRA
DIDANOSINE
SynDRA canonical compound SYN0007470 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · OTC |
|---|
| Primary target(s) | PNP |
|---|
| Mechanism of action | Nucleoside reverse transcriptase inhibitor |
|---|
| Indication | human immunodeficiency virus (HIV-1) |
|---|
| Disease area | infectious disease |
|---|
All known targets
Mechanisms of action (all sources)
- Nucleoside reverse transcriptase inhibitor
- Inhibitor
- pol INHIBITOR
Drug classes
- Nucleoside Reverse Transcriptase Inhibitors
- Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor
- Anti-HIV Agents
- Anti-Infective Agents
- Anti-Retroviral Agents
- Antimetabolites
- Antiviral Agents
- Enzyme Inhibitors
- Noxae
- Nucleic Acid Synthesis Inhibitors
- Reverse Transcriptase Inhibitors
ATC classes
- J05A · DIRECT ACTING ANTIVIRALS
Cross-references
Synonyms
- videx
- dideoxyinosine
- Didanosina
- (-)-didanosine
- Ddi
- Didanosinum
- Dideoxyinosine (ddi)
- BMY-40900
- NSC-612049
- Videx
- Videx ec
- Didanosine system suitability mixture
- DIDEOXYINOSINE
- Videx EC
- Inosine, 2',3'-dideoxy-
- ddIno
- DDI
- BMY 40900
- UNII-K3GDH6OH08
- K3GDH6OH08
- Didanosinum [INN-Latin]
- Didanosina [INN-Spanish]
- CHEBI:490877
- 9-(2,3-Dideoxy-beta-D-ribofuranosyl)-6-oxopurine
- NSC 612049
- 9-[(2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl]-1,9-dihydro-6H-purin-6-one
- 9-[(2R,5R)-5-(HYDROXYMETHYL)TETRAHYDROFURAN-2-YL]-1,9-DIHYDRO-6H-PURIN-6-ONE
- NCGC00159514-02
- NCGC00090691-03
- DRG-0016
- DSSTox_CID_2927
- didanosine system suitability mixture (usp-rs)
- 2',3' Dideoxyinosine
- didanosine (usp monograph)
- didanosine (ep monograph)
- didanosine (usp impurity)
- didanosine system suitability mixture
- didanosine (usp-rs)
Reported adverse events
- Lactic acid
- Lactic acidosis
- Headache
- Nausea
- Pancreatitis
- Rash
- Vomiting
- Non-cirrhotic portal hypertension
Look up DIDANOSINE in the interactive SynDRA portal →